Damon Runyon Researchers

Meet Our Scientists
Xiuning Le, MD, PhD

Mutations in the EGFR gene were identified as the first targetable mutations in lung cancer about two decades ago. Since then, multiple targeted therapies have been approved and prolonged many lives. However, about 15% of EGFR mutations are atypical and do not have a current approved targeted therapy. Dr. Le is leading multiple clinical trials to address this unmet need. With new treatments potentially entering the clinic, new mechanisms of treatment resistance will likely evolve. Dr. Le aims to comprehensively characterize resistance mechanisms and compare resistance predisposition across different types of EGFR-linked lung cancers. She will leverage cutting-edge techniques to determine the mutations at single-cell level and develop rational therapeutic strategies to overcome resistance. This project has the potential not only to bring new FDA-approved treatments to patients but also establish clinical strategies to predict and target major resistance mechanisms.

Project title: "Structure- and lineage-based classification and targeting of resistance in EGFR-mutant NSCLC"
Institution: The University of Texas MD Anderson Cancer Center
Award Program: Clinical Investigator
Sponsor(s) / Mentor(s): John V. Heymach, MD, PhD
Cancer Type: Lung
Research Area: Cancer Genetics